So basically,
Even if we only took 1% of the annual global market for COPD (and that was all we did) at $5 a pop and a conservative PE of 20, the share price should be about 38c.
Still some hurdles to go but RAP is certainly about to wake up, big time!
Ann: ResAppDx-EU for Adult Respiratory Disease Receives CE Mark, page-37
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)